Khalid Alsulaiman Shared a New Study About Clinical Outcomes of Apixaban
Khalid Alsulaiman, Vice Chairman, Clinical Trial Management (CTM) at King Abdullah International Medical Research Center, shared a post on LinkedIn:
“Happy to share our new study titled: “*Evaluation of the Clinical Outcomes of Apixaban Use in Patients with Atrial Fibrillation and Uncontrolled Hypothyroidism: A Real-world Evidence*”, published in Clinical and Applied Thrombosis/Hemostasis.
In this study, we evaluated the effectiveness and safety of apixaban among patients with atrial fibrillation who also suffer from uncontrolled hypothyroidism. Our findings indicate that the use of apixaban in patients with AF and uncontrolled hypothyroidism was linked to higher rates of thrombosis and major bleeding compared to those without known hypothyroidism. These findings highlight the need for further research through larger prospective studies in this often-overlooked population.
We would like to thank all investigators who contributed to this project from the Saudi Critical Care Pharmacy Research (SCAPE) Platform, Saudi Society for Multidisciplinary Research Development and Education (SCAPE Society) and King Abdullah International Medical Research Center (كيمارك KAIMRC).”
Title: Evaluation of the Clinical Outcomes of Apixaban Use in Patients with Atrial Fibrillation and Uncontrolled Hypothyroidism: A Real-world Evidence
Authors: Khalid Al Sulaiman, Manal A Aljohani, Abdullah F Alharthi, Hisham A Badreldin, Mohammed Y Alzahrani, Rahaf A Alqahtani, Walaa A Alshahrani, Fatimah M Abudayah, Mohammad S Shawaqfeh, Ahmed A Alrashed, Alaa M Alenazi, Nouf S Alsagri, Mohammed Yahya Asiri, Zayed Asiri, Sulaiman Aljarallah, Yusuf M. Garwan, Lama S. Alfehaid, Abeer A. Alenazi, Tariq Aldebasi, Shmeylan Alharbi, Ahmed Aldemerdash, Amer Alzahrani, Ohoud Aljuhani

Read full article here.
Stay updated with Hemostasis Today.
-
Jan 7, 2026, 13:57Joshua Muia: Delighted to Welcome X. Long Zheng for a Versiti Seminar on TTP
-
Jan 7, 2026, 13:40Marilena Vrana Invites You to IPPC2026
-
Jan 7, 2026, 13:32Carlos Villa Joins Versiti Blood Research Institute
-
Jan 7, 2026, 13:21Bartosz Hudzik: New Evidence on “Aspirin Failure” After Ischemic Stroke
-
Jan 7, 2026, 08:50Fahad Khaliq on When is Ticagrelor Preferred Over Other Antiplatelets
-
Jan 7, 2026, 06:41Zain Khalpey on AI Driven Risk Prediction for Optimization of Anticoagulation in LVAD
-
Jan 7, 2026, 05:47Michael Makris: The Wakley Prize Essay Published in Today’s Lancet is an Excellent Read
-
Jan 7, 2026, 05:36Pierre F Sabouret Shares A Study on the Risk of Cardiovascular Death in SIDs
-
Jan 7, 2026, 05:15Glaivy Batsuli Reflects on ASH25
